drugset
drugset / Trial / NCT04500132

To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

NCT04500132 ↗

Phase 2 Completed 63 enrolled Enzychem Lifesciences Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

Prevention of COVID-19 infection to severe pneumonea or ARDS

Timeline

Start
2020-05-28
Primary completion
2021-02-04
Completion
2021-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject MOSEDIPIMOD Small molecule — —

Indications

COVID-19